Intercept Pharmaceuticals Inc. was incorporated in the State of Delaware on Sept. 4, 2002. Intercept Pharmaceuticals Inc. has a market cap of $931 million; its shares were traded at around $50.61 with and P/S ratio of 230.10.
President and CEO of Intercept Pharmaceuticals Inc. (ICPT, Financial) Mark Pruzanski sold 37,500 shares on July 9, 2013 at an average price of $46.36. The total transaction amount was $1,738,500.
Mark Pruzanski is the co-founder, president and CEO of Intercept Pharmaceuticals. He has been a member of the board of directors since the start of the company in 2002. Pruzanski has 15 years of experience and previously was a venture partner at Apple Tree Partners, a science venture capital firm that he co-founded in 1999.
President and CEO Mark Pruzanski also sold 37,500 shares of ICPT stock in June. CFO Barbara Gayle Duncan sold 110,000 shares of ICPT stock in May, June and July. Other officers and directors also sold shares.
Intercept Pharmaceuticals Inc. reported its 2012 annual results with licensing revenues of $2.4 million and net loss of $43.6 million.
President and CEO of Intercept Pharmaceuticals Inc. (ICPT, Financial) Mark Pruzanski sold 37,500 shares on July 9, 2013 at an average price of $46.36. The total transaction amount was $1,738,500.
Mark Pruzanski is the co-founder, president and CEO of Intercept Pharmaceuticals. He has been a member of the board of directors since the start of the company in 2002. Pruzanski has 15 years of experience and previously was a venture partner at Apple Tree Partners, a science venture capital firm that he co-founded in 1999.
President and CEO Mark Pruzanski also sold 37,500 shares of ICPT stock in June. CFO Barbara Gayle Duncan sold 110,000 shares of ICPT stock in May, June and July. Other officers and directors also sold shares.
Intercept Pharmaceuticals Inc. reported its 2012 annual results with licensing revenues of $2.4 million and net loss of $43.6 million.
